Health Sciences Building
  • November 8, 2019 from 12:00pm to 1:00pm

Speaker: Joshua Phillipson

Friday, November 8, 2019 – 12pm – 1pm
Health Sciences Building, Room 574
Or join by Zoom Meeting: https://zoom.us/j/895815886

BiondVax’s M-001 universal influenza vaccine candidate is designed to provide multi-season and multi-strain protection against all human influenza virus strains. In 6 completed clinical trials, the vaccine was shown to be safe, well-tolerated and immunogenic to a broad range of flu strains. M-001 is currently undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,000 participants. Results are expected late next year.

 Joshua Phillipson leads business development, marketing, investor and public relations at BiondVax Pharmaceuticals Ltd. He earned an B.Sc. (Hon) from the University of Toronto, participated in the International MPH at Hebrew University in Jerusalem and has an MBA from the Ben-Gurion University of the Negev.